Ann-Lii Cheng

Ann-Lii Cheng is a pioneer in advanced hepatocellular carcinoma clinical trials who led the Asia/Pacific sorafenib SHARP trial and the RESORCE trial establishing regorafenib as the first second-line agent in sorafenib-progressed HCC. His work has been essential in demonstrating that findings from predominantly Western or mixed population trials are applicable to hepatitis B-related HCC prevalent in Asia. He has led or participated in most major HCC systemic therapy trials over two decades and is a central figure in Asia-Pacific oncology.